Vaccine development

The Bundibugyo strain of Ebola has emerged as a significant health threat with a fatality rate reaching up to 50 percent. Currently, there is no approved vaccine available for this particular strain, raising concerns about outbreak containment and public health response.

A new nanodisc-based platform enables researchers to study viral proteins in a virus-like environment, revealing hidden interactions in HIV and Ebola that traditional methods missed. This breakthrough could accelerate the development of more effective vaccines by improving understanding of how antibodies recognize viruses.